Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Otsuka Signs MOU To Invest $83 Million In Korea By 2013

This article was originally published in PharmAsia News

Executive Summary

SEOUL - Japan's Otsuka Pharmaceuticals signed a memorandum of understanding with Korea's health ministry to invest roughly KRW100 billion ($83 million) in research and development of new drugs as well as for clinical trials over the next five years in Korea

You may also be interested in...



Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster

SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan

Korea Begins To Assess Public Health, Industry Fallout From Japan Disaster

SEOUL - While a growing number of countries such as the U.S., Italy, France, Australia, New Zealand, Britain, China, India and Kyrgyzstan are urging their nationals in Japan to evacuate, South Korea on Thursday started checking radiation levels of people coming into the country from Japan

Novartis Signs MOU To Invest $100 Million In R&D, Exchanges With Korean Scientists By 2013

SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences

Related Content

UsernamePublicRestriction

Register

SC072747

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel